| Detected | Trial | Change |
|---|---|---|
| 2026-06-12 | NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… |
date change Primary completion pushed: 2026-04-30 -> 2027-06-30 |
| 2026-06-12 | NCT05950464 Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… |
date change Completion pushed: 2026-04-30 -> 2027-06-30 |
| 2026-06-12 | NCT05691491 Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their… |
Enrollment reduced: 58 -> 42 participants |
| 2026-06-04 | NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… |
date change Primary completion pushed: 2025-09-29 -> 2026-06-14 |
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Primary completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-29 | NCT05396833 Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… |
date change Completion pushed: 2026-04-10 -> 2027-01-14 |
| 2026-05-29 | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… |
date change Primary completion pushed: 2026-03-30 -> 2026-09-30 |
| 2026-05-29 | NCT05882734 Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… |
date change Completion pushed: 2026-03-30 -> 2026-09-30 |
| 2026-05-14 | NCT05828082 Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer |
date change Primary completion pushed: 2026-06-18 -> 2027-01-01 |
| 2026-05-14 | NCT05828082 Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer |
date change Completion pushed: 2026-06-18 -> 2027-01-01 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 2 | |||
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | Endometrial Cancer | Recruiting |
| NCT07417761 | Tuvusertib in Astrocytoma With ATRX Mutation | Astrocytoma | Recruiting |
| NCT05828082 | Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer | Castration-Resistant Prostate Carcinoma | Active, Not Recruiting |
| NCT05947500 | Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to… | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Active, Not Recruiting |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian… | Ovarian Cancer | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC… | Non-Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 1 | |||
| NCT05687136 | Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib… | Advanced Malignant Solid Neoplasm | Recruiting |
| NCT05950464 | Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the… | Recurrent Endometrial Carcinoma | Recruiting |
| NCT06421935 | M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501) | Advanced Solid Tumor | Active, Not Recruiting |
| NCT04170153 | Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |
| NCT05396833 | Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune… | Metastatic or Locally Advanced Unresectable Solid Tumors | Active, Not Recruiting |